• 2016-05-16

    为健康动物做明显标记的染料或颜料,通常有以下2种限制: 1. 染料往往是活性的,因此不容易褪色,并有强烈的产品活性成分。 2. 颜料活性低,不粘附皮肤,所以容易被清洗。 目标要求是研发一种能在动物体上染色的环保材料(如:染料,颜料或其他) 或者一种配方能够达到相同效果。 投标截止时期2016年5月29日, 投标网址https://www.innocentive.com/ar/challenge/9933850 原文 Challenge Overview The Seeker to this Challenge has a cleaning product for animal hygiene to which the Seeker intends to add the capability to stain skin with a clear, visible mark. Various dyes and pigments exist with the potential to provide this feature, however two limitations have been found: • Dyes tend to be reactive, hence not staining and consuming the active ingredient of the product. • Pigments are less reactive, do not adhere to skin, and are therefore easily washed out. The Challenge is to develop a highly colored version of the cleaning product adding to it the ability to stain animal skin. Hence, the Seeker is looking for ideas for ingredients (dyes, pigments, or others) and/or formulations that can overcome the above identified limitations and achieve this effect. This is a Theoretical Challenge that requires only a written proposal to be submitted. The Challenge award will be contingent upon theoretical evaluation of the proposal by the Seeker. Submissions to this Challenge must be received by 11:59 PM (US Eastern Time) on May 29, 2016. Late submissions may not be considered. To receive an award, the Solvers will have to transfer to the Seeker their exclusive Intellectual Property (IP) rightsto the solution.

    征文征稿
    已结束
  • 2016-05-16

    再生药的发展领域,主要集中在修复和取代受损细胞组织或病源组织。干细胞有自我修复功能。胚胎干细胞可以开发成身体内任何形式的细胞组织,成体干细胞的功能是维护或修复身体内部的细胞。Boiheringer Ingelheim的寻找目标是:调动,刺激,分化新的内源性干细胞分子结构的途径。 投标截止时期2016年6月24日, 投标网址:https://www.innocentive.com/ar/challenge/9933855 原文 Mobilization, Stimulation, and Differentiation of Endogenous Stem Cells TAGS: Chemistry, Royal Society of Chemistry, Life Sciences, Ideation AWARD: $15,000 USD | DEADLINE: 6/24/16 | ACTIVE SOLVERS: 51 | POSTED: 4/25/16 1. The Challenge and qualification for the award During early development, embryonic stem cells are undifferentiated cells that can be stimulated to proliferate and develop into all different cell types. In adults, these endogenous cells are found in tissues and they can divide either to replenish the stem cell population or differentiate into specialized cells of the tissue in which they reside. These adult stem cells function as an internal maintenance or repair system, so it would be beneficial to be able to direct and enhance this regenerative capacity. Therefore, Boehringer Ingelheim (the Seeker) desires the identification of new molecular mechanisms and pathways involved in mobilization, stimulation, and differentiation of endogenous stem cells. All submitted solutions will be considered for the award. There will be a guaranteed award for at least one submitted solution. The total payout will be $15,000, with the possibility to distribute it amongst one or more Solvers, with at least one award being no smaller than $5,000 and no award being smaller than $1,000. 2. Additional application for Research Funding In addition to consideration for the award for the submitted solutions, Solvers with appropriate qualifications and expertise having access to a suitable research laboratory and equipment can apply for research funding (“Research Funding”) to execute the research plan that is proposed in the solution. The selection of candidates for Research Funding will be conducted after completion of this Challenge and will require the submission of additional information. The decision to fund research will be at the discretion of the Seeker. This is an Ideation Challenge with a guaranteed award for at least one submitted solution. Submissions to this Challenge including additional optional application for Research Funding must be received by 11:59 PM (US Eastern Time) on June 24, 2016. Late submissions will not be considered. Source: InnoCentive Challenge ID: 9933855 Sign Agreement For This Challenge By electronically signing the agreement below, you are indicating your intention to view the details of this specific InnoCentive Challenge. Viewing the Challenge Details does not obligate you to perform any work on this challenge. Print this Agreement for your records InnoCentive Ideation Challenge-Specific Agreement Please Read This Carefully! You (hereinafter also the “Solver”) and InnoCentive, Inc (hereinafter “InnoCentive”) hereby agree on a Challenge-Specific Agreement for this particular InnoCentive Ideation Challenge only. The Seeker for this InnoCentive Challenge has required that you accept these special terms, so please take the time to understand them. Please note that terms not expressly defined herein shall have the same meaning as defined in the Solver Terms of Use or as provided in any other document related to this specific InnoCentive Challenge. If you click \\"I agree\\" and proceed to the Project Room for this InnoCentive Challenge, this Challenge-Specific Agreement (\\"CSA\\") will be a valid and binding agreement for all purposes relating to this InnoCentive Challenge (including your potential application for Research Funding) and will be applicable in addition to your agreement to abide by the Solver Terms of Usewhen you registered as a Solver. Please print and keep a copy of this CSA. No provisions of any other agreement regarding other InnoCentive Challenges you may have agreed to earlier will apply to this specific InnoCentive Challenge. 1. Proposed Solutions. As a Solver you may submit to InnoCentive your idea (your \\"Proposed Solution\\") to the InnoCentive Ideation Challenge to which this CSA relates (\\"InnoCentive Challenge®\\"). InnoCentive will make reasonable efforts to transmit Proposed Solutions to Seekers; however, nothing herein shall be construed as requiring InnoCentive to transmit every Proposed Solution on an InnoCentive Challenge to a Seeker. In addition, by submitting your Proposed Solution you thereby agree to provide reasonable assistance and additional information concerning your Proposed Solution to InnoCentive or the Seeker, if requested. 2. Application for Research Funding. As a Solver you may, in addition to the provision of the Proposed Solution, apply for Seeker’s Research Funding as outlined in the InnoCentive Challenge Statement. The application for such additional option is only open to you if you (i) provide an additional research plan together with the Proposed Solution, (ii) are appropriately qualified and experienced to execute such research plan, (iii) have access to a suitable research laboratory and equipment, and (iv) are willing to enter into a research collaboration with the Seeker. The statement “I would like to be considered for research funding. I am affiliated with a research institution and have access to a suitable research laboratory and equipment.” must be expressly included in the application for Research Funding. By applying for Research Funding you agree that you receive Seeker contact information for the subsequent negotiation of a research collaboration should your application for Research Funding be selected by the Seeker. By contacting the Seeker you agree to provide contact and other personal information to the Seeker. Awarding a solution is independent from and does not automatically lead to a selection for Research Funding. 3. Acceptance of Proposed Solution. InnoCentive will notify you within a commercially reasonable period of time after the end of the time period set forth in the InnoCentive Challenge Statement whether your Proposed Solution has been selected by Seeker for an Award. The Seeker will judge all Proposed Solutions against the guidelines set out in the InnoCentive Challenge Statement and determine, in its sole discretion, which Proposed Solution best addresses the InnoCentive Challenge Statement guidelines. The Seeker has absolute and sole discretion to determine whether to accept your Proposed Solution, or any Proposed Solution, and whether to make an Award, or multiple Awards. Solver acknowledges and agrees that InnoCentive is not responsible for and has no liability for selection of a winning solver. Solver further agrees to hold InnoCentive legally harmless in regard to selection of a winning solver. Solver agrees to hold InnoCentive legally harmless for any advice it may provide as to the quality or suitability of submitted solutions and agrees to waive any claim against InnoCentive for Solver\'s failure to win an award. The meeting of the InnoCentive Challenge Statement guidelines does not automatically mean that the Proposed Solution will be eligible for an Award. Proposed Solutions must NOT contain or include ideas, concepts, solutions or technology in respect of which a third party owns or controls the intellectual property. Proposed Solutions and descriptions thereof may not include trademarks or trade names of corporations or entities without the permission of their owners. 4. By entering, you represent and warrant that: • your entire Proposed Solution is an original work by you and you have not included third-party content (such as writing, text, graphics, artwork, logos, photographs, dialogue from plays, likeness of any third party, musical recordings, clips of videos, television programs or motion pictures) in or in connection with your Proposed Solution, unless (a) otherwise requested by the Seeker and/or disclosed by you in your Proposed Solution, and (b) you have either obtained the rights to use such third-party content or the content of the Proposed Solution is considered in the public domain without any limitations on use; • no person or entity other than you has any right, title or interest in any part of your Proposed Solution; • unless otherwise disclosed in the Proposed Solution, the use thereof by Seeker, or the exercise by Seeker of any of the rights granted by you under this Agreement, does not and will not infringe or violate any rights of any third party or entity, including, without limitation patent, copyright, trademark, trade secret, defamation, privacy, publicity, false light, misappropriation, intentional or negligent infliction of emotional distress, confidentiality, or any contractual or other rights; • you have all the rights, licenses, permissions and consents necessary to submit the Proposed Solution and to grant all of the rights that you have granted to Seeker hereunder, including the right for Seeker to use and develop derivative works of and from the Proposed Solution; • all persons who were engaged by you to work on the Proposed Solution or who appear in the Proposed Solution in any manner have: a. given you their express written consent to submit the Proposed Solution for unlimited, royalty-free use, exhibition and other exploitation in any manner and in any and all media, whether now existing or hereafter discovered, throughout the world, in perpetuity; b. provided written permission to include their name, image or pictures in or with your Proposed Solution (or if a minor who is not your child, you must have the permission of their parent or legal guardian) and you may be asked by Seeker to provide permission in writing; c. no claims for payment of any kind, including, without limitation, for royalties or residuals, has no approval or consultation rights or any rights of participation arising out of any use, exhibition or other exploitation of the Proposed Solution; and d. not been and are not currently under any union or guild agreement that results in any ongoing obligations resulting from the use, exhibition or other exploitation of the Proposed Solution; and • you understand, recognize and accept that Seeker has access to, may create or has created materials and ideas which may be similar or identical to the Proposed Solution in concept, theme, idea, format or other respects. You acknowledge and agree that Seeker shall have the right to use such same or similar materials, and that you will not be entitled to any compensation arising from Seeker\'s use of such materials. In the event that your entry is identical or similar to the Proposed Solution of another Solver, Seeker reserves the right, at the sole discretion of the Seeker, to either score one Proposed Solution higher than the other subject to the InnoCentive Challenge Statement guidelines or to randomly choose a Proposed Solution from all of those submitted which respond to the InnoCentive Challenge Statement guidelines. Please also be aware that your Proposed Solution may not be acknowledged and will not be received or held \\"in confidence\\" and your Proposed Solution does not create a confidential relationship or obligation of secrecy between you and any of the entities involved in this Challenge. 5. License to use. By entering Solver agrees that all tangible or digital copies of the submitted Proposed Solutions become Seeker\'s property and will not be returned. Each Solver agrees to grant to seeker, by submitting the Proposed Solution, to the fullest extent permissible by applicable law a non-exclusive, royalty free, worldwide, irrevocable, perpetual, assignable and sub-licensable license to the intellectual property rights in the idea or concept demonstrated by the Proposed Solution, in particular for the purpose of research, development, manufacturing and/or commercial use. This license includes the right to use, make, have made, market, copy, lease, sell distribute, and create derivate works of the Proposed Solution and the intellectual property rights in the idea or concept demonstrated by the Proposed Solution. Such right further contains the right to modify and adapt the Proposed Solution and to use the modified solution in the above extent. In addition, Seeker and its licensees, successors and assignees have the right to use any and all Proposed Solutions, and the names, likenesses, voices and images of all persons appearing in the Proposed Solution, for future advertising, promotion and publicity in any manner and in any medium now known or hereafter devised throughout the world in perpetuity. 6. Ownership of intellectual property rights. For the avoidance of doubt, all intellectual property rights, if any, in the idea or concept demonstrated by the Proposed Solution to this challenge will remain with the solver. 7. Payments. If a Seeker Accepts your Proposed Solution, the payment amount (called an \\"Award\\") specified in the InnoCentive Challenge posted on the Service by a Seeker (or, in the case of partial payments of Awards, a \\"Revised Award Amount\\", if applicable) shall be paid to you by InnoCentive within thirty (30) days after occurrence of each of the following: 1) you are notified by lnnoCentive of your Proposed Solution’s acceptance, and 2) the completion of certain verification procedures by InnoCentive, and review and acceptance of such results by Seeker, and 3) InnoCentive’s receipt of Award payment from the Seeker. Payment of any Award is conditioned upon your cooperation with InnoCentive\'s verification procedures. The Award will be paid to you locally, in U.S. Dollars, or if required by your local law, in your local currency equivalent based on the foreign exchange rate in effect on the date of the disbursement by InnoCentive. InnoCentive is not responsible for payment of any Award, or any part of any Award, to any party other than to the Solver through whom the Proposed Solution was submitted to the Service. You understand that the Award represents a complete payment, net of any local taxes that InnoCentive may be required to withhold, for any Accepted Proposed Solution and that you are not entitled to any other compensation of any kind. If local law does not require withholding of taxes, all taxes on Awards shall be your sole responsibility. 8. GENERAL CONDITIONS, Personal Data. InnoCentive and/or Seeker has the right to verify each Solver\'s eligibility and compliance with this CSA, and to terminate any Solver’s registration or participation in a Challenge on the basis of its investigation. Participation is conditioned on providing the data required on the online registration form. Personal data will be processed in accordance with InnoCentive\'s Privacy Policy which can be located athttp://www.innocentive.com/privacy.php. Solvers should direct any request to access, update, or correct information to InnoCentive. Neither InnoCentive nor Seeker is responsible for human error, theft, destruction, or damage to Proposed Solutions, or other factors beyond its reasonable control. InnoCentive is solely responsible for the utilization of its platform by Solvers and Seekers; the Seeker in no event intends to commission any processing of personal data to InnoCentive while using the InnoCentive platform. Solvers should not register with multiple e-mail and/or street addresses. In the event of a dispute as to any Proposed Solution, the authorized account holder of the email address used to enter will be deemed to be the person who submitted the Proposed Solution. The authorized \\"account holder\\" is the natural person assigned an email address by an Internet access provider, online service provider or other organization responsible for assigning email addresses for the domain associated with the submitted address. 9. Representations and Warranties. You represent and warrant that: • All information provided by you regarding yourself and, if applicable, your business (\\"Solver Information\\") is true, accurate, current, and complete information and you will maintain and update the Solver Information to keep it true, accurate, current and complete. • If you are an individual representing a business or other entity, you are authorized to enter into this CSA on behalf of that business or entity. • Unless otherwise disclosed in the Proposed Solution, you are the owner of the Proposed Solution and the Proposed Solution does not infringe or violate any patent, copyright, trade secret, trademark or other third-party intellectual property right. • You have the right to grant the license in the Proposed Solution as required by Section 2 of this CSA. • In the event any of above obligation has been infringed by Solver, Solver shall indemnify and hold harmless the seeker from all damages, liabilities, and/or penalties claimed by third parties due to the infringement of their intellectual property right. 10. Third Party Beneficiary. You and InnoCentive acknowledge and agree that the Seeker shall be a third-party beneficiary of this CSA, and shall have the right to assert and enforce the provisions of this CSA directly on its own behalf. 11. Conflict. In the case of any conflict between the terms of this CSA and the Solver Terms of Use, this CSA controls.

    征文征稿
    已结束
  • 2016-05-13

    通常粘合假牙的化学物会从边缘过量留出,造成的在口中含有化学味道,同时伴随红肿等不良性。寻求一种取代现有的粘合技术,从而改善顾客体验的一种新的技术。 投标截止时期2016年6月5日, 投标网址:https://www.innocentive.com/ar/challenge/9933824 Seeking New Technologies for Denture Adhesives TAGS: Chemistry, Physical Sciences, Life Sciences, Engineering/Design, Theoretical-IP Transfer AWARD: $20,000 USD | DEADLINE: 6/05/16 | ACTIVE SOLVERS: 50 | POSTED: 5/05/16 The use of denture adhesives often comes with an unpleasant sensorial experience for the user, for example, an unpleasant chemical taste, “swelling” and over-flow of the product (oozing) from the edges of the denture and a grainy texture in the mouth. The Seeker for this Challenge is looking to improve this experience for consumers, hence is seeking novel alternative adhesive technologies that can better the sensorial experience without compromising holding performance. This Challenge requires only a written proposal. Source: InnoCentive Challenge ID: 9933824 Sign Agreement For This Challenge By electronically signing the agreement below, you are indicating your intention to view the details of this specific InnoCentive Challenge. Viewing the Challenge Details does not obligate you to perform any work on this challenge. Print this Agreement for your records InnoCentive Theoretical (IP Rights Transfer) Challenge-Specific Agreement Please Read This Carefully! You and InnoCentive are agreeing to a Challenge-Specific Solver Agreement for this particular InnoCentive Challenge only, as permitted in the Terms of Use. The Seeker for this InnoCentive Challenge has required that you accept these special terms, so please take the time to understand them. If you click \\"I agree\\" and proceed to the Project Room for this InnoCentive Challenge, this Challenge-Specific Agreement (\\"CSA\\") will be a valid and binding agreement for all purposes relating to this InnoCentive Challenge and in addition to your agreement to abide by the Terms of Use when you registered as a Solver. Please print and keep a copy of this CSA. No provisions you may have agreed to that are specific to any other individual InnoCentive Challenge will apply. 1. Your Responsibility to Avoid Obstacles. InnoCentive needs to know that if you solve the InnoCentive Challenge there will not be any legal obstacles to completing the sale of your rights to InnoCentive, which is the only way that you can receive the Award. You agree to be responsible for avoiding obstacles to transferring all Intellectual Property and Work Product (altogether, the \\"Solution IP\\") if you submit a Proposed Solution chosen as a Solution. IT IS YOUR RESPONSIBILITY TO DETERMINE YOUR ABILITY TO TRANSFER THE SOLUTION IP. BY SUBMITTING A PROPOSED SOLUTION, YOU REPRESENT TO SEEKER THAT THERE ARE NO OBSTACLES TO SUCH TRANSFER.You will not receive an Award if you cannot transfer the Solution IP. 2. Your Guarantee. You agree that if and when the time comes to transfer the Solution IP, you will give a guarantee (the \\"Guarantee\\") that the transfer is lawful in exchange for the one-time payment of the Award to you alone, and that no consents, approvals or contracts that you did not already have before starting the InnoCentive Challenge are necessary from or with anyone else, such as: a. Your employer; b. Any former employer or other entity you are or have been associated with or have a contract with regarding Intellectual Property you develop; c. Anyone collaborating with you on the development of the Solution IP; d. Anyone else whose Intellectual Property you use or incorporate in the Solution IP; e. Any government official, regulatory body or other authority (for example, if any of the Solution IP is within the scope of a technology export control law in your country prohibiting its transfer to InnoCentive in the United States, or if the required assignments or licenses of the Solution IP are otherwise subject to public registration, review and/or approval) f. The holder of any lien (for example, if a bank or other creditor has obtained a mortgage or security interest in any of the Solution IP); g. Anyone who may be entitled to royalties or other payments relating to any of the Solution IP either by law or contract. 3. Your Obligations to Protect Potential Solution IP. In order to be eligible for an Award, during the period from when you begin work on the InnoCentive Challenge until the expiration of the Time Period as set forth in the Challenge Statement, you shall not: a. Grant away any rights in the Work Product or Proposed Solution you are developing (\\"Potential Solution IP\\"), or do anything else that would prevent you from granting the Option for the Exclusivity Period; b. Reveal to any third party, except on terms of strict confidentiality, any information that relates to Potential Solution IP or do anything else likely to impair any of the Potential Solution IP; or c. Do anything that would cause the failure of your Guarantee. 4. Exclusivity Period. By submitting your Proposed Solution you agree to grant to InnoCentive and the Seeker the following rights, for a period of 180 days (the \\"Exclusivity Period\\") from the deadline set forth in the InnoCentive Challenge Statement (the \\"Deadline\\"): (a) an exclusive option to acquire the rights to the Proposed Solution for use in connection with the InnoCentive Challenge (the \\"Option\\"), as described in this Agreement, and (b) a non-exclusive, worldwide license to use, copy, distribute and create derivative works of the Proposed Solution and the associated work product (the \\"Work Product\\") for purposes of review, analysis and testing the Proposed Solution on a theoretical basis, (collectively, these nonexclusive rights and the Option are referred to as the \\"Exclusive Option Rights\\"). InnoCentive will make reasonable efforts to transmit relevant Proposed Solutions to Seekers, however, nothing herein shall be construed as requiring InnoCentive to transmit every Proposed Solution submitted in Proposed Solution to an InnoCentive Challenge to a Seeker. In addition, by submitting your Proposed Solution you thereby agree to provide reasonable assistance and additional information concerning Work Product and your Proposed Solution to InnoCentive or the Seeker during the Exclusivity Period, if requested. By granting the Exclusive Option Rights you agree that during the Exclusivity Period (and thereafter, if the Option is exercised), you are prohibited from (x) using, the Proposed Solution or the Work Product or (y) disclosing to or granting or assigning or transferring any rights to a third party to use the Proposed Solution or the Work Product for any purpose, including the application for patents or similar intellectual property rights. 5. Validation of Winners. Once the Shortlist of Proposed Solutions has been selected, additional due diligence checks will take place prior to any final Awards being issued. These may include (but are not limited to) completion of a conflict of interest questionnaire, anti-bribery, anti-corruption, human rights screening, and checks to ensure the information provided in the application is genuine. The Seeker is only able to grant the Awards if all the criteria and due diligence checks are completed satisfactorily in the opinion of the Seeker. 6. Acceptance of Proposed Solution and Transfer of Intellectual Property. InnoCentive will notify you within a commercially reasonable period of time after the Deadline and before the termination of the Exclusivity Period whether a Seeker accepts your Proposed Solution and wishes to exercise an Option (\\"Acceptance\\"). For purposes of this Agreement, \\"Acceptance\\" shall mean the selection of your Proposed Solution by the Seeker as meeting the Solution Acceptance Criteria as set forth in the InnoCentive Challenge Statement. The Seeker has absolute and sole discretion to determine whether to Accept your Proposed Solution, or any Proposed Solution, and whether to make an Award, multiple Awards or any Award. Solver acknowledges and agrees that InnoCentive is not responsible for and has no liability for selection of a winning solver, if any. Solver further agrees to hold InnoCentive legally harmless in regard to selection of a winning solver, if any. Solver agrees to hold InnoCentive legally harmless for any advice it may provide as to the quality or suitability of submitted solutions and agrees to waive any claim against InnoCentive for Solver\'s failure to win an award. The meeting of the Solution Acceptance Criteria does not mean that the Proposed Solution will be Accepted by a Seeker. In the event that your Proposed Solution is not Accepted within the Exclusivity Period, the Exclusive Option Rights will terminate without further notice to you and Seeker will retain no rights to the Proposed Solution or the Work Product. Upon Acceptance of your Proposed Solution by a Seeker and payment of an Award to you (see \\"Payments\\"), you hereby assign and convey to InnoCentive, as escrow agent for Seeker, all rights, title, and interests in and to the Proposed Solution and any Work Product that are related to the InnoCentive Challenge, and you retain no rights to the Proposed Solution or the Work Product insofar as they are related to the InnoCentive Challenge. In the event that the Work Product cannot be assigned and conveyed under statutory law, you herewith grant to InnoCentive, as escrow agent for Seeker, a worldwide, unlimited, perpetual, irrevocable, and exclusive license to use, make, have made, market, copy, modify, lease, sell, distribute, and create derivative works of the Work Product, including the right to assign the foregoing license to Seekers (all such rights collectively referred to as \\"Intellectual Property\\"). If you utilize any processes in development of the Work Product which are the subject of patent rights owned by you, you agree to grant to InnoCentive, as escrow agent for Seeker, a worldwide, non-exclusive, perpetual, royalty-free right and license to practice any patented processes used in the Work Product. Furthermore, you agree that you will, during the term of this Agreement and at any time thereafter, execute all papers and do all things deemed necessary by InnoCentive or a Seeker to ensure that the Seeker acquires all rights, title, and interests in and to the Solution and any Work Product that are related to the InnoCentive Challenge, including the rights to all Intellectual Property embodied therein, and that ensures that all such rights are transferred to Seeker. Such cooperation and execution shall be performed without additional compensation to you; provided, however, InnoCentive shall reimburse you for reasonable out-of-pocket expenses incurred at the specific request of InnoCentive. Upon payment of the Award, or termination of the Exclusive Option Rights for any reason, there will be no further obligations between you and InnoCentive or the Seeker with respect to the Proposed Solution, the Work Product, or the InnoCentive Challenge, except for the limitations on use and disclosure described under \\"Confidentiality\\", below. 7. Escrows. The transfers of Solution IP and the Award or any Revised Award Amount (as determined by Seeker) will be in escrow as follows: a. Your transfer of the Solution IP will be to InnoCentive as escrow agent for the Seeker. The Solution IP will be released from this escrow and transferred to the Seeker upon the occurrence of (a) the completion of InnoCentive\'s verification of you; (b) the Seeker\'s payment of the Award to InnoCentive; and (c) the Seeker\'s payment of any other fees of InnoCentive pursuant to the separate agreement between Seeker and InnoCentive. b. The Seeker\'s payment of the Award will be to InnoCentive as escrow agent for you. The Award will be released from this escrow and transferred to you as soon as payment is due to you. 8. Payments. If a Seeker Accepts your Proposed Solution, the payment amount (called an \\"Award\\") specified in the InnoCentive Challenge posted on the Service by a Seeker (or, in the case of partial payments of Awards, a \\"Revised Award Amount\\", if applicable) shall be paid to you by InnoCentive within thirty (30) days after occurrence of each of the following: 1) you are notified by lnnoCentive of your Proposed Solution’s Acceptance, and 2) the completion of certain verification procedures by InnoCentive, and review and acceptance of such results by Seeker, and 3) InnoCentive’s receipt of Award payment from the Seeker.. Payment of any Award is conditioned upon your cooperation with InnoCentive\'s verification procedures and due diligence checks conducted by Seeker under clause 5. The Award will be paid to you locally, in U.S. Dollars, or if required by your local law, in your local currency equivalent based on the foreign exchange rate in effect on the date of the disbursement by InnoCentive. InnoCentive is not responsible for payment of any Award, or any part of any Award, to any party other than to the Solver through whom the Proposed Solution was submitted to the Service. You understand that the Award represents a complete payment, net of any local taxes that InnoCentive may be required to withhold, for any Accepted Proposed Solution and that you are not entitled to any other compensation of any kind. If local law does not require withholding of taxes, all taxes on Awards shall be your sole responsibility. 9. Confidentiality. During the term of this Agreement and at all times thereafter, you shall not disclose to any third party nor use for any purpose other than for the performance of this Agreement, any Confidential Information (as defined below) without the express written consent of the owner of the Confidential Information. These confidentiality obligations shall not apply to Confidential Information which: (a) is in the public domain, or which was publicly known or available on the date you originally accepted this Agreement (\\"Effective Date\\"); or (b) after the Effective Date becomes available to the public in a manner not involving a breach of any duty under this Agreement. Nothing herein shall preclude the ultimate disclosure of any information required by law. \\"Confidential Information\\" includes: • All information set forth in the password protected areas and Project Rooms of the Service (\\"Service Information\\"), (the presentation of Service Information via the Service shall not be deemed to be a public disclosure for purposes of this Agreement and shall not operate as an exclusion from Confidential Information); and • During any Exclusivity Period and after Acceptance and exercise of an Option relating to a InnoCentive Challenge, any Work Product or Proposed Solution relating to said InnoCentive Challenge. The same restrictions on disclosure and use of Confidential Information described in this Section shall apply to the use or disclosure by InnoCentive and Seekers of any Work Product or Proposed Solution during the Exclusivity Period and, if the Proposed Solution is not accepted, thereafter, unless the Proposed Solution or Work Product can be shown by business records of Seeker or InnoCentive to (1) have been known to them previously; (2) is independently created by personnel of Seeker who had no access to the Proposed Solution or the Work Product; or (3) is subject to the exceptions to Confidentiality in (a) or (b) of this section; provided, however, notwithstanding the foregoing, nothing in this Solver Agreement shall prevent a Seeker from utilizing a Solution, for which an Award has been paid, to the extent that a Solution and any rejected Proposed Solution contain overlapping Work Product. Notwithstanding anything herein to the contrary, you recognize that other persons may have provided Seeker or others, or made public, or may in the future submit, or make public, materials that are the same or similar to your Proposed Solution. You acknowledge and agree that Seeker shall have the right to use such same or similar materials, and that you will not be entitled to any compensation arising from Seeker\'s use of such materials. 10. Disclosure of Transfers of Value • Seeker has made an ongoing commitment to transparency in its dealings with healthcare professionals and healthcare organisations worldwide; • Seeker is required to publicly disclose transfers of value it makes to healthcare professionals and healthcare organisations under the European Federation of Pharmaceutical Industries and Associations Code on disclosures of transfer of value from pharmaceutical companies to healthcare professionals and healthcare organisations (“EFPIA Code”); • A transfer of value for these purpose means the Award payment, and any expenses that may be incurred in connection with the grant of the Award which Seeker reimburses to you. • The payments to be made by Seeker under this engagement are transfers of value that Seeker is required to publicly disclose under the EFPIA Code; • Your name and contact details (other than email address) will be included in reports that Seeker will publish on publicly accessible websites, along with details of the transfers of value made, to meet Seeker’s transparency reporting obligations; • Disclosures will be made on the basis of the most recent information Seeker has received from you. • Seeker will publish details of all transfers of value made to you from 1 January 2016. Reports will be published annually on a publicly accessible website or another platform, such as a central platform provided by EFPIA and this publication will be maintained for at least 3 years. • Prior to publication/disclosure, Seeker will provide you with a statement of the transfers of value it proposes to disclose against your name; • You acknowledge and agree that these disclosures will be made. 11. ETHICAL STANDARDS AND HUMAN RIGHTS Unless otherwise required or prohibited by law, you warrant, to the best of your knowledge, that in relation to the Proposed Solution: • you do not employ engage or otherwise use any child labour in circumstances such that the tasks performed by any such child labour could reasonably be foreseen to cause either physical or emotional impairment to the development of such child; • you do not use forced labour in any form (prison, indentured, bonded or otherwise) and your employees are not required to lodge papers or deposits on starting work; • you provide a safe and healthy workplace, presenting no immediate hazards to your employees. Any housing provided by you to your employees is safe for habitation. You provide access to clean water, food, and emergency healthcare to your employees in the event of accidents or incidents at your workplace; • you do not discriminate against any employees on any ground (including race, religion, disability or gender); • you do not engage in or support the use of corporal punishment, mental, physical, sexual or verbal abuse and do not use cruel or abusive disciplinary practices in the workplace; • you pay each employee at least the minimum wage, or a fair representation of the prevailing industry wage, (whichever is the higher) and provide each employee with all legally mandated benefits; • you comply with the laws on working hours and employment rights in the countries in which you operate; • you are respectful of your employees’ right to join and form independent trade unions and freedom of association. You agree that you are responsible for controlling your own supply chain and that you shall encourage compliance with ethical standards and human rights by any subsequent supplier of goods and services that are used by you when performing your obligations in relation to the Proposed Solution. You shall ensure that you have ethical and human rights policies and an appropriate complaints procedure to deal with any breaches of such policies. Seeker reserves the right upon reasonable notice (unless inspection is for cause, in which case no notice shall be necessary) to enter your premises to monitor your compliance of the warranties set out above and you shall, subject to compliance with law, furnish Seeker with any relevant documents requested by Seeker in relation thereto. 12. COMPLIANCE WITH LAWS AND ANTI-CORRUPTION • You shall comply fully at all times with all applicable laws and regulations, including but not limited to applicable anti-corruption laws, of the territory in which you conduct business with Seeker. • Where, in the course of working on the Proposed Solution, you will interact with third parties (other than your own sub-contractors) or will interact in any way with healthcare professionals or government officials (as defined in Annex 1), you hereby give the warranties and representations set out in, and shall comply with, the provisions of Annex 1. • Seeker shall be entitled to terminate your participation in a Challenge immediately if you fail to perform your obligations in accordance with this Clause and, where applicable, Annex 1. You shall have no claim against Seeker for compensation for any loss of whatever nature by virtue of the termination of your participation in the Challenge in accordance with this Schedule. To the extent (and only to the extent) that the laws of the territory provide for any such compensation to be paid to you upon the termination of your participation, you hereby expressly agree to waive (to the extent possible under the laws of the territory) or to repay to Seeker any such compensation or indemnity. 13. APPLICATION TO INDIVIDUALS. For the avoidance of doubt, Clauses 11 and 12 above apply to both individuals as well as companies. 14. General Conditions: InnoCentive and/or Seeker has the right to verify each Solver\'s eligibility and compliance with this CSA, and to terminate any Solver\'s registration and participation in a Challenge on the basis of its investigation. Personal data will be processed in accordance with InnoCentive\'s Privacy Policy which can be located at http://www.innocentive.com/privacy.php. Solvers should direct any request to access, update, or correct information to InnoCentive. Neither InnoCentive nor Seeker is responsible for human error, theft, destruction, or damage to Proposed Solutions, or other factors beyond its reasonable control. 15. Third Party Beneficiary. You and InnoCentive acknowledge and agree that any Seeker shall be a third-party beneficiary of this Agreement, and each shall have the right to assert and enforce the provisions of this Agreement directly on its own behalf. 16. Conflict. In the case of any conflict between the terms of this CSA and the Terms of Use, this CSA controls. # # # Annex 1 ANTI BRIBERY AND CORRUPTION REQUIREMENTS 1. You represent that you have not been convicted of or pleaded guilty to a criminal offence, including one involving fraud, corruption, or moral turpitude, that you are not now, to the best of your knowledge, the subject of any government investigation for such offenses, and that you are not now listed by any government agency as debarred, suspended, proposed for suspension or debarment, or otherwise ineligible for government programs. 2. You represent and warrant that, except as disclosed in writing: (1) you do not have any interest which directly or indirectly conflicts with your proper and ethical performance of activites in relation to participation in the Challenge and (2) you shall maintain arms length relations with all third parties (including government officials) with which you deal for or on behalf of Seeker, or in the performance of activities in relation to participation in the Challenge. 3. Seeker shall have the right to conduct an investigation and audit of your business to monitor compliance with the terms of this Annex. You shall cooperate fully with such investigation or audit, the scope, method, nature and duration of which shall be at the sole reasonable discretion of Seeker. 4. You shall ensure that all transactions in relation to participation in the Challenge are properly and accurately recorded in all material respects on your books and records and each document upon which entries such books and records are based is complete and accurate in all material respects. You must maintain a system of internal accounting controls reasonably designed to ensure that you maintain no off-the-books accounts. 5. You agree that Seeker may make full disclosure of information relating to a possible violation of these terms at any time and for any reason to any competent government bodies and its agencies, and to whomsoever Seeker determines in good faith has a legitimate need to know. PREVENTION OF CORRUPTION – THIRD PARTY GUIDELINES Seeker’s Anti-Bribery and Corruption Policy requires compliance with the highest ethical standards and all anti-corruption laws applicable in the countries in which Seeker (whether through a third party or otherwise) conducts business. The policy requires all Seeker employees and any third party acting for or on behalf of Seeker to ensure that all dealings with third parties, both in the private and government sectors, are carried out in compliance with all relevant laws and regulations and with the standards of integrity required for all Seeker business. Seeker values integrity and transparency and has zero tolerance for corrupt activities of any kind, whether committed by Seeker employees, officers, or third-parties acting for or on behalf of the Seeker. Corrupt Payments – Seeker employees and any third party acting for or on behalf of Seeker, shall not, directly or indirectly, promise, authorise, ratify or offer to make or make any “payments” of “anything of value” (as defined in the glossary section) to any individual (or at the request of any individual) including a “government official” (as defined in the glossary section) for the improper purpose of influencing or inducing or as a reward for any act, omission or decision to secure an improper advantage or to improperly assist the company in obtaining or retaining business. Government Officials – Although Seeker´s policy prohibits payments by Seeker or third parties acting for or on its behalf to any individual, private or public, as a “quid pro quo” for business, due to the existence of specific anticorruption laws in the countries where we operate, this policy is particularly applicable to “payments” of “anything of value” (as defined in the glossary section), or at the request of, “government officials” (as defined in the glossary section). Facilitating Payments – For the avoidance of doubt, facilitating payments (otherwise known as “greasing payments” and defined as payments to an individual to secure or expedite the performance of a routine government action by government officials) are no exception to the general rule and therefore prohibited. You shall not contact, or otherwise meet with any Government Official with respect to any transactions required in relation to participation in the Challenge, without the prior written approval of Seeker and, when requested by Seeker, only in the presence of a Seeker designated representative. GLOSSARY The terms defined herein should be construed broadly to give effect to the letter and spirit of the ABAC Policy. Seeker is committed to the highest ethical standards of business dealings and any acts that create the appearance of promising, offering, giving or authorising payments prohibited by this policy will not be tolerated. Anything of Value: this term includes cash or cash equivalents, gifts, services, employment offers, loans, travel expenses, entertainment, political contributions, charitable donations, subsidies, per diem payments, sponsorships, honoraria or provision of any other asset, even if nominal in value. Payments: this term refers to and includes any direct or indirect offers to pay, promises to pay, authorisations of or payments of anything of value. Government Official shall mean: • Any officer or employee of a government or any department, agency or instrument of a government; • Any person acting in an official capacity for or on behalf of a government or any department, agency, or instrument of a government; • Any officer or employee of a company or business owned in whole or part by a government; • Any officer or employee of a public international organisation such as the World Bank or United Nations; • Any officer or employee of a political party or any person acting in an official capacity on behalf of a political party; and/or • Any candidate for political office

    工艺技术
    已结束
  • 2016-05-13

    寻找一种可以代替粘结剂(胶水)粘结聚合材料的方法,聚合材料如:织物,橡胶,泡沫或胶片。粘合效果必须是长久有效的,并且优于粘合剂如:性价比,快速粘合时间。 投标截止时期2016年5月30日, 投标网址:https://www.innocentive.com/ar/challenge/9933860 Bonding of Polymeric Materials without Adhesives TAGS:CChemistry \\ Physical Sciences \\ Engineering \\ Design \\ Royal Society of Chemistry AWARD: $10,000 USD | DEADLINE: 5/30/16 | ACTIVE SOLVERS: 123 | POSTED: 4/28/16 The Seeker is looking for alternative methods to bond specific polymeric materials together other than adhesives. These polymeric materials can be in many forms including fabrics, rubber, foams and films. The bond must be durable and offer advantages over adhesives like cost and time savings. This Theoretical Challenge requires only a written proposal. Source: InnoCentive Challenge ID: 9933860 Sign Agreement For This Challenge By electronically signing the agreement below, you are indicating your intention to view the details of this specific InnoCentive Challenge. Viewing the Challenge Details does not obligate you to perform any work on this challenge. Print this Agreement for your records InnoCentive Theoretical (IP Rights Transfer) Challenge-Specific Agreement Please Read This Carefully! You and InnoCentive are agreeing to a Challenge-Specific Solver Agreement for this particular InnoCentive Challenge only, as permitted in the Terms of Use. The Seeker for this InnoCentive Challenge has required that you accept these special terms, so please take the time to understand them. If you click \\"I agree\\" and proceed to the Project Room for this InnoCentive Challenge, this Challenge-Specific Agreement (\\"CSA\\") will be a valid and binding agreement for all purposes relating to this InnoCentive Challenge and in addition to your agreement to abide by the Terms of Use when you registered as a Solver. Please print and keep a copy of this CSA. No provisions you may have agreed to that are specific to any other individual InnoCentive Challenge will apply. 1. Your Responsibility to Avoid Obstacles. InnoCentive needs to know that if you solve the InnoCentive Challenge there will not be any legal obstacles to completing the sale and assignment of your rights to InnoCentive (which will, in turn, assign the rights to the Seeker), which is the only way that you can receive the Award. You agree to be responsible for avoiding obstacles to transferring all Intellectual Property and Work Product (altogether, the \\"Solution IP\\") if you submit a Proposed Solution chosen as a Solution. IT IS YOUR RESPONSIBILITY TO DETERMINE YOUR ABILITY TO TRANSFER THE SOLUTION IP. BY SUBMITTING A PROPOSED SOLUTION, YOU REPRESENT TO INNOCENTIVE AND SEEKER THAT THERE ARE NO OBSTACLES TO SUCH TRANSFER. You will not receive an Award if you cannot transfer the Solution IP. 2. Your Guarantee. You agree that if and when the time comes to transfer the Solution IP, you will give a guarantee (the \\"Guarantee\\") that the transfer is lawful in exchange for the one-time payment of the Award to you alone, and that no consents, waivers, approvals, agreements or contracts that you did not already have before starting the InnoCentive Challenge are necessary from or with anyone else, such as by way of example: a. Your employer (or, if you are a consultant, contracting entity); b. Any former employer or other entity you are or have been associated with or have a contract with regarding Intellectual Property you develop; c. Anyone who collaborated or is collaborating with you on the development of the Solution IP; d. Anyone else whose Intellectual Property you use(d) or incorporate(d) in the Solution IP; e. Anyone who licensed technology or intellectual property to you; f. Any government official, regulatory body or other authority (for example, if any of the Solution IP is within the scope of a technology export control law in your country prohibiting its transfer to InnoCentive in the United States, or if the required assignments or licenses of the Solution IP are otherwise subject to public registration, review and/or approval) g. The holder of any lien (for example, if a bank or other creditor has obtained a mortgage or security interest in any of the Solution IP); h. Anyone who may be entitled to royalties or other payments relating to any of the Solution IP either by law or contract. 3. Your Obligations to Protect Potential Solution IP. In order to be eligible for an Award, during the period from when you begin work on the InnoCentive Challenge until the expiration of the Time Period as set forth in the Challenge Statement, you shall not: a. Grant, license, transfer, and/or assign away any rights in the Work Product or Proposed Solution you are developing (\\"Potential Solution IP\\"), or do anything else that would prevent you from granting the Option for the Exclusivity Period; b. Reveal to any third party, except on terms of strict confidentiality, any information that relates to Potential Solution IP or do anything else likely to impair any of the Potential Solution IP; or c. Do anything that would cause the failure of your Guarantee. You further agree that the identity of any patents or patent applications included in the Potential Solution IP (the “Patents”), any information provided to the Seeker about the Patents, the Seeker’s receipt and/or evaluation of any such information and/or the Patents, and any related discussions between the you and the Seeker (collectively, “Evaluation Activities and Information”) shall not be used as a basis to place the Seeker on notice (e.g., for purposes of willfulness, inducement or otherwise) of the Patents and shall not constitute pre-litigation notice to or knowledge by (or evidence thereof) the Seeker. You agree not to use, and waive the right to use, any Evaluation Activities and Information (including, without limitation, patent numbers) as evidence for any purpose in any judicial, administrative, or other proceeding in which infringement of the patents is alleged against the Seeker. You hereby release and waive all claims for damages based on such Evaluation Activities and Information against the Seeker. Should a claim based on such alleged notice or knowledge be made by you (or your subsequent assignee or another third party) against the Seeker, this CSA may be used by the Seeker to seek to dismiss such a claim. You shall require that any subsequent purchaser and/or assignee of the Patents is obligated to honor the foregoing covenant. Notwithstanding anything to the contrary in this CSA, the foregoing covenant shall survive expiration or termination of this CSA. 4. Exclusivity Period. By submitting your Proposed Solution you agree to grant to InnoCentive and the Seeker the following rights, for a period of ninety (90) days (the \\"Exclusivity Period\\") from the deadline set forth in the InnoCentive Challenge Statement (the \\"Deadline\\"): (a) an exclusive option to acquire the rights to the Proposed Solution for use in connection with the InnoCentive Challenge (the \\"Option\\"), as described in this Agreement, and (b) a non-exclusive, worldwide license to use, copy, distribute and create derivative works of the Proposed Solution and the associated work product (the \\"Work Product\\") for purposes of review, analysis and testing the Proposed Solution on a theoretical basis (collectively, these nonexclusive rights and the Option are referred to as the \\"Exclusive Option Rights\\"). InnoCentive will make reasonable efforts to transmit relevant Proposed Solutions to Seekers, however, nothing herein shall be construed as requiring InnoCentive to transmit every Proposed Solution submitted in an InnoCentive Challenge to a Seeker. In addition, by submitting your Proposed Solution you thereby agree to provide reasonable assistance and additional information concerning Work Product and your Proposed Solution to InnoCentive and/or the Seeker during the Exclusivity Period, if requested. By granting the Exclusive Option Rights you agree that during the Exclusivity Period (and thereafter, if the Option is exercised), you are prohibited from (x) using the Proposed Solution or the Work Product or (y) disclosing to or granting or assigning or transferring any rights to a third party to use the Proposed Solution and/or the Solution IP for any purpose, including the application for patents or similar intellectual property rights. 5. Acceptance of Proposed Solution and Transfer of Intellectual Property. InnoCentive will notify you within a commercially reasonable period of time after the Deadline and before the termination of the Exclusivity Period whether a Seeker accepts your Proposed Solution and wishes to exercise an Option (\\"Acceptance\\"). For purposes of this Agreement, \\"Acceptance\\" shall mean the selection of your Proposed Solution by the Seeker as meeting the Solution Acceptance Criteria as set forth in the InnoCentive Challenge Statement. The Seeker has absolute and sole discretion to determine whether to Accept your Proposed Solution, or any Proposed Solution, and whether to make an Award, multiple Awards or any Award. Solver acknowledges and agrees that InnoCentive is not responsible for and has no liability for selection of a winning solver, if any. Solver further agrees to hold InnoCentive legally harmless in regard to selection of a winning solver, if any. Solver agrees to hold InnoCentive legally harmless for any advice it may provide as to the quality or suitability of submitted solutions and agrees to waive any claim against InnoCentive for Solver\'s failure to win an award. The meeting of the Solution Acceptance Criteria does not mean that the Proposed Solution will be Accepted by a Seeker. In the event that your Proposed Solution is not Accepted within the Exclusivity Period, the Exclusive Option Rights will terminate without further notice to you and Seeker will retain no rights to the Proposed Solution or the Work Product. Upon Acceptance of your Proposed Solution by a Seeker and payment of an Award to you (see \\"Payments\\"), you hereby assign and convey to InnoCentive, as escrow agent for Seeker, all rights, title, and interests in and to the Proposed Solution and any Work Product that are related to the InnoCentive Challenge, and you retain no rights to the Proposed Solution or the Work Product insofar as they are related to the InnoCentive Challenge. In the event that the Work Product cannot be assigned and conveyed under statutory law, you herewith grant to InnoCentive, as escrow agent for Seeker, a worldwide, unlimited, perpetual, irrevocable, and exclusive license to use, make, have made, market, copy, modify, lease, sell, distribute, and create derivative works of the Work Product, including the right to assign the foregoing license to Seekers (all such rights collectively referred to as \\"Intellectual Property\\"). If you utilize any processes in development of the Work Product which are the subject of patent rights owned by you, you agree to grant to InnoCentive, as escrow agent for Seeker, a worldwide, non-exclusive, perpetual, royalty-free right and license to practice any patented processes used in the Work Product, including the right to sublicense the foregoing to the Seeker. Furthermore, you agree that you will, during the term of this Agreement and at any time thereafter, execute all papers and do all things deemed necessary by InnoCentive or a Seeker to ensure that the Seeker acquires all rights, title, and interests in and to the Solution and any Work Product that are related to the InnoCentive Challenge, including the rights to all Intellectual Property embodied therein, and that ensures that all such rights are transferred to the Seeker (the foregoing obligations referred to as the “Continuing Obligations”). Such cooperation and execution shall be performed without additional compensation to you; provided, however, InnoCentive shall reimburse you for reasonable out-of-pocket expenses incurred at the specific request of InnoCentive. Upon payment of the Award, or termination of the Exclusive Option Rights for any reason, there will be no further obligations between you and InnoCentive or the Seeker with respect to the Proposed Solution, the Work Product, or the InnoCentive Challenge, except for the Continuing Obligations and the limitations on use and disclosure described under \\"Confidentiality\\", below. 6. Escrows. The transfers of Solution IP and the Award or any Revised Award Amount (as determined by Seeker) will be managed in escrow and administered by InnoCentive as follows: a. Your transfer of the Solution IP will be to InnoCentive as escrow agent for the Seeker. The Solution IP will be released from this escrow and transferred by InnoCentive to the Seeker upon the occurrence of each of the following: (a) the completion of InnoCentive\'s verification of you; (b) the Seeker\'s payment of the Award to InnoCentive; and (c) the Seeker\'s payment of any other fees of InnoCentive pursuant to the separate agreement between the Seeker and InnoCentive. b. The Seeker\'s payment of the Award will be to InnoCentive as escrow agent for you. The Award will be released from this escrow and transferred to you by InnoCentive as soon as payment is due to you as set forth below in “Payments”. 7. Payments. If a Seeker Accepts your Proposed Solution, the payment amount (called an \\"Award\\") specified in the InnoCentive Challenge posted on the Service by a Seeker (or, in the case of partial payments of Awards, a \\"Revised Award Amount\\", if applicable) shall be paid to you by InnoCentive within thirty (30) days after the occurrence of each of the following: (1) you are notified by lnnoCentive of your Proposed Solution’s Acceptance; (2) the completion of certain verification procedures by InnoCentive, and review and acceptance of such results by the Seeker; and *3) InnoCentive’s receipt of Award payment from the Seeker. Payment of any Award is conditioned upon your cooperation with InnoCentive\'s verification procedures. The Award will be paid to you locally, in U.S. Dollars, or if required by your local law, in your local currency equivalent based on the foreign exchange rate in effect on the date of the disbursement by InnoCentive. InnoCentive is not responsible for payment of any Award, or any part of any Award, to any party other than to the Solver through whom the Proposed Solution was submitted to the Service. You understand that the Award represents a complete payment, net of any local taxes that InnoCentive may be required to withhold, for any Accepted Proposed Solution and that you are not entitled to any other compensation of any kind. If local law does not require withholding of taxes, all taxes on Awards shall be your sole responsibility. 8. Confidentiality. During the term of this Agreement and at all times thereafter, you shall not disclose to any third party nor use for any purpose other than for the performance of this Agreement, any Confidential Information (as defined below) without the express written consent of the owner of the Confidential Information. These confidentiality obligations shall not apply to Confidential Information which: (a) is in the public domain, or which was publicly known or available on the date you originally accepted this Agreement (\\"Effective Date\\"); or (b) after the Effective Date becomes available to the public in a manner not involving a breach of any duty under this Agreement. Nothing herein shall preclude the ultimate disclosure of any information required by law. \\"Confidential Information\\" includes: • All information set forth in the password protected areas and Project Rooms of the Service (\\"Service Information\\"), (the presentation of Service Information via the Service shall not be deemed to be a public disclosure for purposes of this Agreement and shall not operate as an exclusion from Confidential Information); and • During any Exclusivity Period and after Acceptance and exercise of an Option relating to a InnoCentive Challenge, any Work Product or Proposed Solution relating to said InnoCentive Challenge. The same restrictions on disclosure and use of Confidential Information described in this Section shall apply to the use or disclosure by InnoCentive and Seekers of any Work Product or Proposed Solution during the Exclusivity Period and, if the Proposed Solution is not accepted, thereafter, unless the Proposed Solution or Work Product can be shown by business records of Seeker or InnoCentive to (1) have been known to them previously; (2) is independently created by personnel of Seeker who had no access to the Proposed Solution or the Work Product; or (3) is subject to the exceptions to Confidentiality in (a) or (b) of this section; provided, however, notwithstanding the foregoing, nothing in this Solver Agreement shall prevent a Seeker from utilizing a Solution, for which an Award has been paid, to the extent that a Solution and any rejected Proposed Solution contain overlapping Work Product. Notwithstanding anything herein to the contrary, you recognize that other persons, including Seeker, may have independently developed and/or provided to Seeker or others, or made public, or may in the future submit, or make public, materials that are the same or similar to your Proposed Solution. You acknowledge and agree that Seeker shall have the right to use such same or similar materials, and that you will not be entitled to any compensation arising from Seeker\'s use of such materials. 9. General Conditions: InnoCentive and/or Seeker has the right to verify each Solver\'s eligibility and compliance with this CSA, and to terminate any Solver\'s registration and participation in a Challenge on the basis of its investigation. Personal data will be processed in accordance with InnoCentive\'s Privacy Policy which can be located at http://www.innocentive.com/privacy.php. Solvers should direct any request to access, update, or correct information to InnoCentive. Neither InnoCentive nor Seeker is responsible for human error, theft, destruction, or damage to Proposed Solutions, or other factors beyond its reasonable control. 10. Third Party Beneficiary. You and InnoCentive acknowledge and agree that any Seeker shall be a third-party beneficiary of this Agreement, and each shall have the right to assert and enforce the provisions of this Agreement directly on its own behalf. 11. Conflict. In the case of any conflict between the terms of this CSA and the Terms of Use, this CSA controls.

    征文征稿
    已结束
  • 2016-05-13

    理论分析一种材料,能有明显区分其与丙酮或水(潮湿)的物理作用。如膨胀,收缩,卷曲,等等。此材料不限于纤维,膜剂或织物。 “请于2016年5月23日之前将稿件上传到:https://www.innocentive.com/ar/challenge/9933858 “ Challenge Overview Many materials (usually polymers) change shape when exposed to acetone (ketones in general) but also have a large affinity for moisture as well. It would be very difficult to attribute physical changes to acetone or water if both were present. The Seeker is looking for materials and associated processes that produce an observable physical change to the substrate upon exposure to acetone. The material should not have the same effect when exposed to moisture so the two can be differentiated. The effect should be reversible and the rate of absorb/desorb should be similar. This is a Theoretical Challenge that requires only a written proposal to be submitted. The Challenge award will be contingent upon theoretical evaluation of the proposal by the Seeker. To receive an award, the Solvers will have to transfer to the Seeker their exclusive Intellectual Property (IP) rightsto the solution. However, the Seeker will be willing to consider a licensing agreement for a partial award if exclusive IP cannot be transferred by the Solver. Submissions to this Challenge must be received by 11:59 PM (US Eastern Time) on May 23, 2016. Late submissions will not be considered.

    其他
    已结束
  • 2016-05-12

    当心血管疾病(心脏病或中风)确诊后,医生会提供治疗建议,但病人的决定是至关重要的。美国心脏协会(AHA)与 以病人为中心的成果研究所(PCORI)合作,网络征集文章。你可以是患者,社区志愿者,家庭成员或任何人,只要你有这方面的亲身经验。根据你的情况来阐述患者的治疗决策是怎样做出的,例如:对寿命的影响,对生活质量的影响,费用,或其他?同时关心过程的完整性,时间,等等。。。 “请于2016年6月9日之前将稿件上传到:https://www.innocentive.com/ar/workspace/challengeDetail?challenge=9933835“ THE CHALLENGE Treatment of heart disease and stroke often requires patients and their families to make many decisions on how to move forward after a cardiac event. Specifically, AHA and PCORI are interested in learning about the “decisional dilemmas” you face – your insights will help guide future research to improve heart health. Based on the input from you and others in the patient and caregiver community, we will identify important concerns and use the perspectives to target research towards what matters most. Despite multiple available treatment options that your physician may describe, you may not always know which option is right/best for you. Tell us about the most difficult decision that you or your family faced when evaluating treatment options for heart disease or stroke. In addition, we would like to understand more about what you considered most important when making this choice or decision. Please pick your top three choices and tell us why they are important to you and your family: Side effects of the treatment Complexity of treatment plan Difficulty in adhering to a treatment Impact on my quality of life Potential to prolong my life Whether the best option for me is selected based on research of people similar to me (personal characteristics such as my age, race and gender) Whether my family history and genetic makeup would influence the effectiveness of a given option Whether a trusted source recommended a specific option The financial impact of the options for me and my family Other:________ Any submission should address the following Submission Requirements: The submission can be from anyone (patient, caregiver, family member, or other) who has been involved, first-hand, in experiencing the decisions that were made/need to be made in the treatment of heart disease and stroke. The story should be personal in nature and not a general case. The submission must be pertinent to the United States health care system. It should not be based on other country systems. Other systems can be used as examples, but all information must be directed at how it could influence the U.S system. You must use the attached Submission Form. THINGS TO AVOID This Challenge is not meant to focus on complaints about your doctors/nurses or the health care system in general. Rather, the goal is to try to improve treatment based on your own, or a loved one’s, experiences. Please try to focus on the facts and the decision making process related to the treatment of heart disease and stroke. This requires a personal case and story and the decision making must reflect personal experiences. A generalization of heart disease and stroke treatment will not be acceptable/considered. If you are a patient, write about the condition you experienced. Project Criteria Note: All submissions must be on the Submission Form attached to the Challenge. You can find it in the right hand column as you face the Detailed Description of the Challenge. The Submission Form includes some optional demographics data that the Seeker would like you to fill out as well as your response to the Challenge questions. You will just need to save the form, fill it out and upload it as your submission. You can add attachments to your submission if you wish, but you must use the Submission Form to be eligible for an award. Submitted responses should include the information described in the Detailed Description of the Challenge, including: A brief history leading up to important decisions that were made in the treatment of heart/vascular disease or stroke. Each major decision should be described in detail and include: Choices that were given and how they were explained to you. The top three factors (provided above) that influenced your decision the most. Explain why and how they influenced your decision. Discuss what information was helpful that was provided by your doctor and any information that might have been missing, if known. Did you gather additional information from other “trusted sources” of information? What kind of information did you receive? If you could change the way things were done, what would you do to improve your experience in the decision making process concerning the treatment of your heart/vascular disease or stroke? It may be helpful in your response to keep in mind the decision(s) itself, the choices involved, and the considerations for those choices. Format for submission: You should fill out the Submission Form which has boxes for all your information above. You can add attachments, but your primary submission must be on the Submission Form to be eligible for an award. The total text of your submission (the part that you write on the Submission Form) should be ~ 1-3 pages long. Please do not add any title pages, headers, blank pages, etc. The submission should not include any information that you may consider Intellectual Property and do not want to share. Optional participation in providing demographic information with the submission: this information will be held by InnoCentive until after the close of the Challenge and then submitted to AHA and PCORI to help them understand what is most important to patients with similar characteristics/demographics in order to target research to the areas most important to patients and caregivers like you. It will not be used in determining awards. AHA and PCORI may wish to speak with you at the conclusion of the Challenge to clarify and ask a few more questions. Please include a statement indicating your interest in this opportunity. Review Criteria: Submissions will be reviewed by a team of scientific professionals and patient representatives with expertise in heart/vascular disease and stroke. Submissions will be reviewed on: Completeness of addressing the topic of heart/vascular disease and stroke treatment. Discussion of influence factors on decision making. Feasibility as a future research topic (note: Solver is not asked to submit a research plan). Relevance to the decisions made and options available in the United States health care system. This is an Ideation Challenge, which has the following unique features: There is a guaranteed award. The total payout will be $10,000, awarded to a total of ten submitters, at $1,000 each. The winners will only be chosen from those that complete all requirements and deliverables properly as determined by AHA and PCORI. The pool will be among those submissions describing the themes that are ultimately chosen to inform the subsequent researcher-based Challenge. Note: All submissions must be on the Submission Form attached to the Challenge. You can find it in the right hand column as you face this page. The Submission Form includes some optional demographics data that the Seeker would like you to fill out as well as your response to the Challenge questions. You will just need to save the form, fill it out and upload it as your submission. You can add attachments to your submission if you wish, but you must use the Submission Form to be eligible for an award. Submission forwarding occurs during the Challenge. Since submissions will be forwarded to AHA and PCORI throughout the Challenge, please make sure you upload only a finished submission. You can submit an updated version of your submission only as a new submission. If you submit an updated version of your submission/response, please clearly indicate the new items and/or edits compared to your previous submission. This will allow AHA and PCORI to quickly find the new information and determine how it improves your submission. You are not required to transfer exclusive intellectual property rights to AHA and PCORI. Rather, by submitting a response, you grant to AHA and PCORI a royalty-free, perpetual, and non-exclusive license to use any information included in this response.

    征文征稿
    已结束
写私信
  • 10
  • 交易量
  • 3101550
  • 赏金
最近10位访客
  • 药智客

    2023-12-29 14:53
  • 药智客

    2023-11-20 12:34
  • 药智客

    2023-11-03 00:09
  • 药智客

    2023-11-02 16:22
  • 药智客

    2023-10-26 12:38
  • 药智客

    2023-10-09 06:15
  • 药智客

    2023-10-08 22:33
  • 药智客

    2023-10-03 05:54
  • 药智客

    2023-08-26 08:08
  • 药智客

    2023-08-04 15:39